Biomea Fusion (BMEA) awards 452,512 stock options to director and officer Erdtmann

Rhea-AI Filing Summary

Biomea Fusion, Inc. director and officer Rainer M. Erdtmann received a grant of stock options covering 452,512 shares of common stock. The options have an exercise price of $1.49 per share and expire on March 31, 2036.

According to the terms, the award will vest in 16 substantially equal quarterly installments after April 1, 2026, becoming fully vested and exercisable on April 1, 2030, subject to his continued service with the company. Following this grant, he holds 452,512 derivative securities directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Erdtmann Rainer M

Role See Remarks

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	452,512	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 452,512 shares (Direct)

Footnotes (1)

1. [object Object]

Key Figures

Option grant size: 452,512 options Exercise price: $1.49 per share Expiration date: March 31, 2036 +2 more

5 metrics

Option grant size 452,512 options Stock Option (Right to Buy) granted to Rainer M. Erdtmann

Exercise price <money>$1.49</money> per share Exercise price for the granted stock options

Expiration date <date>March 31, 2036</date> Option term end date

Vesting completion date <date>April 1, 2030</date> Date options become fully vested and exercisable

Post-grant derivative holdings 452,512 derivative securities Total options held directly after transaction

Key Terms

Stock Option (Right to Buy), exercise price, vesting, Common Stock

4 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

exercise price financial

"conversion_or_exercise_price: "1.4900" per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"The option shall vest and become exercisable in 16 substantially equal quarterly installments"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

Common Stock financial

"underlying_security_title: "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Erdtmann Rainer M

(Last) (First) (Middle)

C/O BIOMEA FUSION, INC.

1599 INDUSTRIAL ROAD

(Street)

SAN CARLOS CALIFORNIA 94070

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Biomea Fusion, Inc. [ BMEA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.49	04/01/2026		A		452,512		(1)	03/31/2036	Common Stock	452,512	$0	452,512	D

Explanation of Responses:

1. The option shall vest and become exercisable in 16 substantially equal quarterly installments after April 1, 2026, such that the award will be fully vested and exercisable on April 1, 2030, subject to the Reporting Person's continued service to the Issuer through each vesting date.

Remarks:

President, Chief Operating Officer, Principal Financial Officer, and Principal Accounting Officer

	/s/ Rainer M. Erdtmann	04/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Biomea Fusion (BMEA) insider Rainer Erdtmann receive in this Form 4?

Rainer M. Erdtmann received a stock option grant for 452,512 shares of Biomea Fusion common stock. The options are a compensation-related award, not an open-market purchase, and give him the right to buy shares at a fixed exercise price.

What is the exercise price and term of the new BMEA stock options?

The granted stock options have an exercise price of $1.49 per share and expire on March 31, 2036. This means Erdtmann can choose to exercise the options at that price any time after they vest and before they expire.

How do the Biomea Fusion (BMEA) options granted to Erdtmann vest?

The options vest in 16 substantially equal quarterly installments after April 1, 2026. They will be fully vested and exercisable on April 1, 2030, provided Erdtmann continues to serve Biomea Fusion through each vesting date.

Is this BMEA Form 4 a stock purchase or a compensation grant?

This Form 4 reflects a compensation grant, coded as an “A” transaction for an award or acquisition. Erdtmann did not buy shares on the open market; he received options to purchase 452,512 shares at a fixed exercise price in the future.

How many Biomea Fusion derivative securities does Erdtmann hold after this grant?

After the grant, Erdtmann holds 452,512 derivative securities directly, all from this stock option award. These represent rights to acquire Biomea Fusion common shares upon future exercise, subject to vesting and the stated expiration date.

Does the BMEA filing mention any special conditions on the option grant?

Yes. The options vest only if Erdtmann continues his service with Biomea Fusion through each vesting date. Full vesting occurs on April 1, 2030, and the options then remain exercisable until their expiration in 2036.